Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 11

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 11
---
 corporation on August 26, 2021 for the purpose of pursuing the development and commercialization of TELOMIR-1 in the United States in human applications. We were originally incorporated under the name “Metallo Therapies Inc.” and changed our name to “Telomir Pharmaceuticals, Inc.” in October 2022.

Our corporate headquarters is located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131. Our telephone number is (786) 396-6723. Our website address is www.telomirpharma.com. Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.

| 7 |

<div align='center'>USE OF PROCEEDS</div>

Unless we specify another use in the applicable prospectus supplement, we will use the net proceeds from the sale of the securities offered by us for general corporate purposes, which may include, among other things, debt repayment, working capital and/or capital expenditures.

We may also use such proceeds to fund acquisitions of product candidates or technologies that complement our current business. We may set forth additional information on the use of net proceeds from the sale of the securities we offer under this prospectus in a prospectus supplement related to a specific offering.

Investors are cautioned, however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount of competition and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.

From time to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:

| ● | a                                                                                                                           
 change in development plan or strategy;                                                                                     |
| ● | delays                                                                                                                      
 or difficulties with our clinical trials;                                                                                   |
| ● | negative                                                                                                                    
 results from our clinical trials;                                                                                           |
| ● | difficulty                                                                                                                  
 obtaining regulatory approval;                                                                                              |
| ● | failure                                                                                                                     
 to achieve sales as anticipated;                                                                                            |
| ● | the                                                                                                                         
 addition of new product candidates or technologies;